On January, 1 2019, Medicare implemented the home infusion therapy (HIT) benefit as a temporary transitional payment (TTP). The HIT benefit covers professional service visits related to the intravenous or subcutaneous administration of drugs or biologicals to an individual at home. Medicare then permanently implemented the HIT benefit on January 1, 2021. There are two major changes between the TTP and the permanent benefit. First, under the TTP, only durable medical equipment (DME) suppliers could provide HIT service visits. Under the permanent benefit, any qualified HIT supplier who is accredited and enrolled in Medicare can provide HIT service visits. Second, the list of HIT-eligible drugs changed slightly.

Using data from the January 1, 2019 to March 31, 2021, this report highlights changes to the HIT benefit as it transitioned from the TTP to the permanent benefit.

Learn more about Abt’s work on this project.